Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Comment by EternalPonzion Apr 01, 2020 3:25pm
108 Views
Post# 30869557

RE:RE:About time

RE:RE:About time
@Francine. Completely agree. Jan needs to go. Given the current climate I do not expect sp to be anywhere near a 10 banger as some on this board are predicting. Will be lucky to triple within 12 months even with acceptable results. There isn't a big pharma that will offer any kind of rich premium for this company. The health care system is a mess. The return just isn't there and ACST will begin to have money problems in 6 months. Big Pharma holds all the cards. They just have to wait and pick up the pieces. Once again another start-up crashes and burns because of crappy and very likely corrupt management. I'm no longer surprised by anything anyone does anymore. Self-interest ALWAYS determines outcome. Never forget that.
<< Previous
Bullboard Posts
Next >>